Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

March 8, 2023

Study Completion Date

February 29, 2024

Conditions
Advanced MalignanciesSolid TumorHematological Malignancy
Interventions
DRUG

Pelabresib

Pelabresib monohydrate tablets

Trial Locations (10)

17325

Gettysburg Cancer Center, Gettysburg

28040

Madrid - FJD, Madrid

41013

Hospital Universitario Virgen del Rocío, Seville

44718

Gabrail Cancer Center Research, Canton

84119

Start Mountain Region, West Valley City

Unknown

Hight Technology Hospital Medcenter, Batumi

K. Eristavi National Center of Experimental and Clinical Surgery, Tbilisi

Simon Khechinashvili University Hospital, Tbilisi

START CIOCC Hospital HM Sanchinarro, Madrid

08023

Barcelona HM Nou Delfos, Barcelona

Sponsors
All Listed Sponsors
lead

Constellation Pharmaceuticals

INDUSTRY

NCT05391022 - Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies | Biotech Hunter | Biotech Hunter